Medivation Bulls Are Back for More

David Russell | Writer, OptionMonster
Tuesday, 2 Jul 2013 | 5:24 AM ET

Medivation has already made a big move, but the bulls are looking for more.

Back on May 29, OptionMonster's trade scanners detected buying in the July 50 calls for $3.50. The investor rolled a long position in those contracts yesterday, selling 2,250 contracts for $5.25 and buying an equal number of August 55 calls for $5.85.

Calls lock in the price where shares can be purchased in the drug developer, letting investors cheaply position for a move higher. Adjusting the trade cost $0.60 and gives him or her an additional month of upside exposure.

What's Working in Pharma
Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.

Medivation jumped 5.77 percent to $52.04 yesterday and is up 11 percent in the last week. The stock rose more than 400 percent between November 2011 and October 2012, but has been drifting mostly sideways since then. The recent activity suggests that further gains are expected soon.

Calls accounted for more than 70 percent volume, so the session's overall tone was definitely bullish. More than 8,000 contracts traded yesterday, compared with the daily average of 1,200.

—By CNBC Contributor David Russell

Additional News: High Court's GenericDrug Ruling 'a Holy Mess'

Additional Views: Bidding Up the Price of Cancer Cures

Options Trading School:


David Russell is a reporter and writer for OptionMonster.Russell has no positions in MDVN.



  Price   Change %Change